• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    40 Stocks Moving In Friday's Mid-Day Session

    6/3/22 12:07:35 PM ET
    $ACOR
    $AMLX
    $BQ
    $BTOG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

     

    Gainers

    • Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares jumped 32.8% to $1.4740 after declining around 9% on Thursday.
    • Nutex Health, Inc. (NASDAQ:NUTX) gained 20.6% to $11.11.
    • Sprague Resources LP (NYSE:SRLP) shares jumped 19.8% to $18.96 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit.
    • Kubient, Inc. (NASDAQ:KBNT) gained 19.5% to $1.19.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 18.9% to $11.62 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.
    • Boqii Holding Limited (NYSE:BQ) jumped 15.5% to $2.26.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) jumped 14.7% to $2.27.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) gained 14% to $45.82.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose 14.6% to $10.42. Nurix Therapeutics will present trial in progress posters for three clinical programs Jun. 4 and 5.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) gained 13.6% to $7.50. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 1,000,000 shares at at an average price of $6.60.
    • Society Pass Incorporated (NASDAQ:SOPA) jumped 13.1% to $2.3626 after the company announced it acquired Gorilla Networks.
    • Houston American Energy Corp. (NYSE:HUSA) jumped 12% to $4.9600.
    • Calavo Growers, Inc. (NASDAQ:CVGW) gained 11.7% to $37.08 following better-than-expected Q2 results.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) surged 11.6% to $0.3839.
    • Okta, Inc. (NASDAQ:OKTA) rose 11.3% to $104.28 after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 10.6% to $1.36 after dropping 13% on Thursday.
    • Quanex Building Products Corporation (NYSE:NX) gained 8.7% to $22.55 after the company reported better-than-expected Q2 results and issued FY22 sales guidance above estimates.
    • The Marygold Companies, Inc. (NYSE:MGLD) rose 8.5% to $1.5950. Marygold Companies, last month, posted Q1 earnings of $0.02 per share.
    • StoneCo Ltd. (NASDAQ:STNE) rose 6.6% to $11.11 after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s guidance of R$1.85 billion and R$1.9 billion.
    • CN Energy Group. Inc. (NASDAQ:CNEY) rose 6.1% to $1.6011 after dipping 26% on Thursday.

     

    Losers

    • Bit Origin Limited (NASDAQ:BTOG) shares dipped 41.9% to $0.5001 after the company priced a 9,803,922 share offering at $0.51 per share.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares fell 35.2% to $0.39 after the company reported pricing of $4 million underwritten public offering.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 19.8% to $0.6750.
    • HashiCorp, Inc. (NASDAQ:HCP) shares dipped 18.8% to $33.51 after the company reported Q1 earnings results and issued guidance.
    • JOANN Inc. (NASDAQ:JOAN) dropped 18.1% to $6.47 after the company said Q1 EPS results were lower year over year and reported worse-than-expected Q1 sales results.
    • Novavax, Inc. (NASDAQ:NVAX) fell 17.2% to $46.36. The U.S. FDA published briefing documents on Novavax Covid-19 vaccine for individuals aged 18 and older.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) dropped 15.6% to $0.8436. Zosano Pharma recently announced it filed a voluntary petition for relief under chapter 11.
    • Rallybio Corporation (NASDAQ:RLYB) declined 15.1% to $11.23. Rallybio announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) shares fell 15% to $0.85. Zosano Pharma shares tumbled 43% on Thursday after the company announced it filed a voluntary petition for relief under chapter 11.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) declined 13.8% to $0.60.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 13.6% to $0.2878.
    • Minerva Neurosciences, Inc. (NASDAQ:NERV) dipped 12.4% to $0.3703.
    • Context Therapeutics Inc. (NASDAQ:CNTX) declined 10.5% to $1.96.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) dropped 10.4% to $2.10.
    • Wayfair Inc. (NYSE:W) dipped 8.7% to $58.22.
    • Talkspace, Inc. (NASDAQ:TALK) fell 8.5% to $1.61 after jumping 34% on Thursday.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) dropped 8% to $0.7598.
    • Zhong Yang Financial Group Limited (NASDAQ:TOP) fell 6.1% to $15.21 amid post-IPO volatility.
    • Zumiez Inc. (NASDAQ:ZUMZ) fell 5.2% to $32.38 after the company reported worse-than-expected Q1 EPS results and issued Q2 EPS and sales guidance below analyst estimates.

     

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AMLX
    $BQ
    $BTOG

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    4/20/2026$90.00Equal Weight → Overweight
    Barclays
    Okta Inc.
    $OKTA
    4/16/2026$85.00Mkt Perform → Outperform
    Raymond James
    Minerva Neurosciences Inc
    $NERV
    4/15/2026$14.00Mkt Outperform
    Citizens
    Okta Inc.
    $OKTA
    3/19/2026$100.00Outperform
    Macquarie
    Okta Inc.
    $OKTA
    3/6/2026$97.00Market Perform → Outperform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    3/3/2026$76.00Equal Weight
    Wells Fargo
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Okta Inc.
    $OKTA
    2/26/2026$90.00 → $83.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wendte Erin Denise claimed ownership of 73,419 shares (SEC Form 3)

    3 - Zumiez Inc (0001318008) (Issuer)

    4/24/26 4:16:23 PM ET
    $ZUMZ
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form 4 filed by Director Reed Michael Lee

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:35:38 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Saunders Scott J

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/24/26 2:32:08 PM ET
    $NUTX
    Real Estate

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    StoneCo Files Its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

    George Town, Grand Cayman--(Newsfile Corp. - April 23, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") hereby informs its shareholders and the market that has filed today, April 23, its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC").The report is available on the SEC's website, at www.sec.gov, and on StoneCo's Investor Relations website, at https://investors.stone.co. About StoneCoStone Co. is a leading provider of financial technology solutions that empower merchants to conduct commerce seamlessly across multiple channels and help them grow their businesses with our payments, banking, and cre

    4/23/26 6:02:00 PM ET
    $STNE
    EDP Services
    Technology

    Nutex Health Schedules 2026 First Quarter Financial Results Release and Conference Call

    HOUSTON, April 22, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the first fiscal quarter ended March 31, 2026, on Thursday, April 30, 2026 after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, May 1, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and provide a b

    4/22/26 4:15:00 PM ET
    $NUTX
    Real Estate

    NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

    NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only "Minor" administrative changesNRx conducted a meeting with leadership of the FDA Office of Generic Drugs in which support was voiced for the potential approval of the Abbreviated New Drug Application within the current review cycle.Ketamine is identified as medically necessary by the US Department of Veterans Affairs for the treatment of suicidality and treatment-resistant depression.In addition to the current ANDA, NRx is in the process of submitting a New Drug Application to align the labeling of ketamine with its use in treating depression and suicidalityThe President's April 16, 2

    4/22/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    4/24/26 9:28:23 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-4/A filed by Rallybio Corporation

    S-4/A - Rallybio Corp (0001739410) (Filer)

    4/24/26 4:38:43 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Zumiez Inc.

    DEFA14A - Zumiez Inc (0001318008) (Filer)

    4/24/26 4:00:14 PM ET
    $ZUMZ
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Okta upgraded by Barclays with a new price target

    Barclays upgraded Okta from Equal Weight to Overweight and set a new price target of $90.00

    4/20/26 8:21:07 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Okta upgraded by Raymond James with a new price target

    Raymond James upgraded Okta from Mkt Perform to Outperform and set a new price target of $85.00

    4/16/26 7:58:53 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Citizens initiated coverage on Minerva Neurosciences with a new price target

    Citizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00

    4/15/26 8:09:21 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

    Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this fieldMr. Tyson is appointed as NRx anticipates approval of an ANDA for preservative-free ketamine and near term submission of a New Drug Application to expand ketamine labeling to encompass depression and suicidality. WILMINGTON, Del., April 13, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company's first

    4/13/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Financials

    Live finance-specific insights

    View All

    Nutex Health Schedules 2026 First Quarter Financial Results Release and Conference Call

    HOUSTON, April 22, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the first fiscal quarter ended March 31, 2026, on Thursday, April 30, 2026 after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, May 1, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and provide a b

    4/22/26 4:15:00 PM ET
    $NUTX
    Real Estate

    StoneCo Announces Extraordinary Dividend

    George Town, Grand Cayman--(Newsfile Corp. - April 14, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") today announced that its Board of Directors has approved the payment of an extraordinary cash dividend of $2.53 per share of the company (both Class A and Class B shareholders) to be paid on May 4th, 2026 to shareholders of record as of April 24th, 2026. Based on shares outstanding on March 31st, the total amount of cash to be paid in the dividend will be approximately R$3.08 billion.The board has also approved an increase of approximately 3.8mm of shares related to the Long Term Incentive Plan pool, which shall be settled in accordance with the vesting schedule of the respect

    4/14/26 6:11:00 PM ET
    $STNE
    EDP Services
    Technology

    Calavo Growers Declares Quarterly Dividend

    SANTA PAULA, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (Nasdaq-GS: CVGW) (the "Company" or "Calavo") a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, previously announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on the Company's outstanding common stock. On April 13, 2026, the Board of Directors amended the record date for the previously declared dividend from April 1, 2026 to April 24, 2026. Except for the change in the record date, the dividend remains unchanged in all respects, including the amount of $0.20 per share and the pa

    4/13/26 7:35:00 AM ET
    $CVGW
    Specialty Foods
    Consumer Discretionary

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HashiCorp Inc.

    SC 13G/A - HashiCorp, Inc. (0001720671) (Subject)

    11/14/24 5:45:37 PM ET
    $HCP
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by HashiCorp Inc.

    SC 13G/A - HashiCorp, Inc. (0001720671) (Subject)

    11/14/24 5:42:58 PM ET
    $HCP
    EDP Services
    Technology